CLDI Calidi Biotherapeutics, Inc.: רווח למניה לשנה מתגלגלת

Calidi Biotherapeutics (CLDI) is developing scalable stem cell-based oncolytic platforms with high margin potential. The annual percentage growth of EPS TTM on the GURU.Markets consolidated chart has reached 53.90, reflecting the metric's current level. This accompanies the brand's evolution as an innovator in targeted drug delivery to tumors. Investor confidence is supported by stable leadership effectively building partnerships with global clinics.

This indicator reflects the rate of change in net income per share over a rolling year. The metric's calculation logic allows for an assessment of the business's actual earnings growth rate by excluding seasonal fluctuations. Analyzing the annual net income per share growth rate (TTM) helps identify false price impulses. For Calidi Biotherapeutics (CLDI), such dynamics will serve as a marker for the monetization of its patented drug delivery platform. The high pricing power of the therapy should translate into an acceleration of this fundamental trend.